Logistics boost: A technician checking the production line of the first batch of Sinovac Biotech’s Covid-19 vaccine CoronaVac at Pharmaniaga Life Science’s plant in Puchong. The firm’s upside is its earnings contribution from the Covid-19 vaccine supply and distribution.
PETALING JAYA: Pharmaniaga Bhd
is expected to see a normalisation in demand for financial year 2021 (FY21) after witnessing a decline in revenue for FY20.
The company’s FY20 revenue dipped 3.4% as it saw lower sales from its core concession business for its logistics and distribution (L&D) segment due to disruptions in demand from both the public and private healthcare facilities.
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
